Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
Patent 4427660 Issued on January 24, 1984. Estimated Expiration Date: 
March 3, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 3, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.InventorsAssigneeApplicationNo. 06/354357 filed on 03/03/1982US Classes:514/18, 3 or 4 peptide repeating units in known peptide chain530/330, 4 to 5 amino acid residues in defined sequence530/331, Tripeptides, e.g., tripeptide thyroliberin (TRH), melanostatin (MIF), etc.930/190, Antibiotic930/20, Containing modified or unusual amino acid (See note 1 and note 2)930/280, Bound to a nonpeptide drug, nonpeptide label, nonpeptide carrier, or a nonpeptide resin930/290Polyamino acid or polypeptide with an uninterrupted series of peptide repeating unitsExaminersPrimary: Phillips, Delbert R.Attorney, Agent or FirmInternational ClassesA61K 38/04 (20060101)C07K 5/00 (20060101) C07K 5/083 (20060101) C07K 5/103 (20060101) A61K 38/00 (20060101) AbstractA group of synthetic N-formyl methionine tri and tetra peptides in covalent combination with antibiotics are useful in treating infections. These peptideantibiotic conjugates exhibit a high degree of chemotactic activity for polymorphonuclear leukocytes and monocytes while simultaneously inhibiting the growth of microorganisms. The use of chemotactic peptide-silver sulfadiazine conjugates is particularly effective for treating burns.Other References
|
| ||||||||||||||
